Skip to Main Content

There’s an enzyme in the body that regulates what scientists refer to as “the bliss molecule,” a neurotransmitter associated with generally feeling good. And thus it made sense that blocking that enzyme, called FAAH, might be a useful way to combat feeling bad, like in cases of chronic pain or depression. 

And so a bunch of drug companies fashioned FAAH inhibitors and tested them in dozens of trials, only for each one to prove too weak or too toxic to become an actual medicine. This went on until around 2015, when the industry seemed to just move on from FAAH.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.